Stocks and InvestingStocks and Investing
Wed, February 23, 2022
Tue, February 22, 2022
Sun, February 20, 2022
Fri, February 18, 2022
Thu, February 17, 2022

Andrew Berens Downgraded (BPMC) to Hold and Decreased Target to $82 on, Feb 17th, 2022


Published on 2024-10-27 19:43:33 - WOPRAI, Andrew Berens
  Print publication without navigation


Andrew Berens of SVB Leerink, Downgraded "Blueprint Medicines Corporation" (BPMC) to Hold and Decreased Target from $93 to $82 on, Feb 17th, 2022.

Andrew has made no other calls on BPMC in the last 4 months.



There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022


These are the ratings of the 3 analyists that currently disagree with Andrew


  • Bradley Canino of "Stifel" Upgraded from Hold to Strong Buy and Decreased Target to $95 on, Tuesday, January 25th, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021